Published online Sep 18, 2022. doi: 10.5500/wjt.v12.i9.281
Peer-review started: June 10, 2022
First decision: July 12, 2022
Revised: July 19, 2022
Accepted: August 12, 2022
Article in press: August 12, 2022
Published online: September 18, 2022
Processing time: 91 Days and 7.9 Hours
Non-alcoholic fatty liver disease (NAFLD) is one of the leading causes of chronic liver disease, cirrhosis, and hepatocellular carcinoma worldwide, with an esti
Core Tip: Non-alcoholic fatty liver disease (NAFLD) is a common complication in liver transplant recipients. Despite the rising prevalence and potentially progressive nature of this entity, there are currently no recommendations regarding NAFLD diagnosis and management in the post-transplant setting. Future studies are urgently needed to fill this knowledge gap and define optimal diagnostic and treatment approaches in this patient population.
- Citation: Kalogirou MS, Giouleme O. Growing challenge of post-liver transplantation non-alcoholic fatty liver disease. World J Transplant 2022; 12(9): 281-287
- URL: https://www.wjgnet.com/2220-3230/full/v12/i9/281.htm
- DOI: https://dx.doi.org/10.5500/wjt.v12.i9.281
Non-alcoholic fatty liver disease (NAFLD) is characterized by the presence of steatosis in at least 5% of hepatocytes in the absence of any secondary causes, such as excessive alcohol consumption or other chronic liver diseases[1]. NAFLD encompasses a wide spectrum of histological findings, ranging from simple steatosis (non-alcoholic fatty liver, NAFL) to non-alcoholic steatohepatitis (NASH), the latter of which is additionally characterized by lobular inflammation and hepatocyte ballooning[2]. NAFL is generally considered a slowly progressive or non-progressive condition, while NASH is associated with an increased risk of disease progression to cirrhosis and hepatocellular carcinoma[3].
NAFLD has become the leading cause of chronic liver disease worldwide, with an estimated prevalence of 25%, which is constantly rising in parallel to the worldwide obesity pandemic[4]. NAFLD is often considered the hepatic component of the metabolic syndrome and is associated with other metabolic disorders, such as obesity, type 2 diabetes mellitus (T2DM), dyslipidemia, and insulin resistance (IR)[5]. Due to the increasing prevalence and high risk of progression, NASH has become the second most common indication for liver transplantation (LT) in the United States, reporting a 170% increase from 2004 to 2013[6,7]. LT leads to the resolution of NASH-related complications; however, the underlying metabolic risk factors remain, and are even exacerbated following LT, resulting in a high rate of post-LT NAFLD recurrence[8]. In addition, many recipients are prone to develop a post-LT metabolic syndrome (PTMS), mainly due to the reversal of the cirrhosis-related catabolic state and immunosuppression side effects, leading to de novo NAFLD[9].
Recurrence of steatosis and steatohepatitis in recipients with a pre-transplant diagnosis of NASH is more common compared to de novo NAFLD, with a prevalence ranging between 8% and 100% in a follow-up period of 1-10 years[10]. Yalamanchili et al[11] studied 257 patients transplanted for NASH or cryptogenic cirrhosis. Post-LT steatosis was reported in 31% of patients; however, bridging fibrosis or cirrhosis was only found in 5% and 10% of recipients after 5 years and 10 years, respectively[11]. In a recent retrospective study of 275 NASH recipients, the prevalence of NAFLD and NASH recurrence was 22% and 11%, respectively[12]. However, it should be underlined that most studies have important heterogeneity regarding NAFLD diagnosis and patient selection. Recipients with cryptogenic cirrhosis as an indication for LT were included in most of these studies, resulting in a possible NAFLD recurrence overdiagnosis[11,13,14].
De novo NAFLD is defined as the presence of steatosis or steatohepatitis in patients who underwent LT for indications other than NASH[15]. Up to one-third of liver transplant recipients develop de novo NAFLD depending on a combination of host and graft factors[16,17]. Dumortier et al[16] studied 599 non-NASH liver transplant recipients and reported a prevalence of de novo NAFLD of 31%[16]. The authors demonstrated several independent risk factors for the occurrence of post-LT de novo steatosis, such as post-LT obesity, tacrolimus-based immunosuppression therapy, diabetes mellitus, and pre-transplant liver graft steatosis, demonstrating a dose-dependent relationship between the number of these risk factors and the risk of developing de novo NAFLD. In a recent meta-analysis by Losurdo et al[15] the pooled prevalence of de novo NAFLD and NASH was 26% and 2%, respectively, at a follow-up period of 6 mo to 10 years[15]. The highest prevalences were observed in patients transplanted for either alcoholic (37%) or cryptogenic cirrhosis (35%), or those receiving tacrolimus (26%). Data remain, however, scarce regarding these entities, while the retrospective design and small sample size of most studies represent important limitations.
Several risk factors have been associated with post-LT NAFLD occurrence (Table 1). As mentioned above, the pre-transplant metabolic risk factors persist following LT, despite the resolution of liver disease. In addition, the commonly used maintenance immunosuppressive regimens, namely corticosteroids, calcineurin inhibitors (CNIs), and mammalian targets of rapamycin (mTOR) inhibitors are directly linked to obesity, hypertension, dyslipidemia, and hyperglycemia, exacerbating the existing metabolic profile of transplanted patients or leading to a new-onset PTMS. Recipients are at high risk of developing PTMS, irrespective of LT indication, with an estimated prevalence ranging from 44%-58% at 6 mo following LT[17]. The presence of PTMS has been associated with both recurrent and de novo NAFLD[16,18,19]. Pre-transplant graft-steatosis, genetics, and other recipient-related risk factors appear to contribute to the development of both recurrent and de novo NAFLD in the transplanted population[20]. In a recent observational study of 108 recipients, it was concluded that recipient-related factors are more important than donor-related factors in the development of NAFLD, following LT[21].
Recipient factors | Donor factors |
Obesity/post-LT weight gain | Macrovesicular graft steatosis |
T2DM | Genetics |
Dyslipidemia | |
Genetics | |
Immunosuppression | |
LT indication: NASH, HCV, ALD |
Several studies have attempted to reveal the role of genetic predisposition in the development of post-LT NAFLD. Both recipient and donor genetics have been associated with an increased risk of graft steatosis. The role of patatin-like phospholipase domain-containing protein 3 (PNPLA3) in the development of NAFLD is well established. Finkenstedt et al[22] showed that LT recipients who carry rs738409-GG in PNPLA3 are at increased risk of post-LT NAFLD[22]. In another study of 176 liver transplant patients, Trunečka et al[23] demonstrated that the expression of PNPLA3 p.148M variant in donors represents an independent risk factor for graft steatosis[23]. The donor transmembrane 6 superfamily member 2 c.499A allele was also associated with a higher risk of steatosis in recipients[24]. John et al[25] found that recipient, but not donor, adiponectin polymorphisms rs1501299 G/G and rs17300539 G/G were related to a higher prevalence of post-LT graft steatosis[25].
The maintenance immunosuppressive agents used after LT can exacerbate a preexisting metabolic syndrome in recipients, or lead to a new-onset PTMS, thereby contributing to the development of recurrent and de novo NAFLD[26]. Corticosteroids are widely used in the immediate post-operative period against allograft rejection. They increase the hepatic output of glucose and decrease insulin production and peripheral glucose uptake, inducing IR. Corticosteroid use has been associated with an increased risk of T2DM, dyslipidemia, hypertension, and rapid weight gain in recipients following LT[27]. CNI therapy (cyclosporine and tacrolimus) is also recognized as a risk factor for metabolic syndrome and consequent post-LT NAFLD. They are linked to hypertension, dyslipidemia, new-onset T2DM, and chronic renal disease, with tacrolimus having a more prominent diabetogenic effect compared to cyclosporine, which is mainly associated with post-transplant hypertension[26,28,29]. However, studies investigating the direct association between CNI therapy and post-LT NAFLD seem to provide conflicting results[16,30,31]. Another commonly used class of immunosuppressive drugs, mTOR inhibitors, appear to have metabolic adverse effects, being associated with significant dyslipidemia and IR[26]. Sirolimus increases adipose tissue lipase activity and decreases lipoprotein lipase activity, resulting in hypertriglyceridemia, especially with concomitant cyclosporine therapy[32,33]. In a retrospective study of 430 post-LT biopsies, Galvin et al[31] reported that sirolimus use was predictive of de novo NAFLD following LT[31].
Donor steatosis has also been suggested as a potential risk factor for post-LT de novo and recurrent NAFLD. While microvesicular steatosis does not affect graft function or survival, donor livers with severe macrovesicular steatosis have been associated with an increased risk of primary graft dysfunction, inferior graft survival, and requirement for retransplantation[34]. However, there is not enough evidence to support the predictive role of donor steatosis in the development of post-LT NAFLD. Three studies have indicated an association between pre-existing donor graft steatosis and post-LT NAFLD, whereas findings in a meta-analysis by Saeed et al[35] did not support this association[16,35-37].
Aside from NASH, specific other LT indications have been associated with an increased risk of de novo NAFLD. Recipients with a pre-transplant diagnosis of alcoholic liver disease (ALD) are at higher risk of developing de novo post-LT steatosis[16,30]. Hepatitis C virus infection was also reported as a risk factor for post-LT NAFLD[31,38]. In a meta-analysis by Losurdo et al[15], the authors reported the highest prevalence of de novo NAFLD in patients that underwent an LT for ALD and cryptogenic cirrhosis (37% and 35%, respectively)[15].
Despite the high prevalence of recurrent and de novo NAFLD following LT, progression to NASH and advanced fibrosis is less frequent in these patients. Dumortier et al[16] reported recurrent steatosis in 31% of recipients; however, NASH and advanced fibrosis/cirrhosis were only observed in 3.8% and 2.25% of patients[16]. Yalamanchili et al[11] confirmed these findings, reporting similarly low incidence rates of NASH and cirrhosis in patients with post-LT NAFLD (4% and 10%, respectively)[11]. However, in the meta-analysis by Saeed et al[35], the authors reported significantly higher rates of recurrent and de novo NASH (38% and 17%, respectively)[35]. Overall survival of patients transplanted for NASH-related cirrhosis is comparable to those with non-NASH indications in most studies[39-41]. In a recent retrospective analysis of 68950 patients that underwent LT for end-stage liver disease of various indications, Haldar et al[42] confirmed the aforementioned findings and demonstrated a patient survival at 1, 5, and 10 years post-LT of 84.1%, 73.4%, and 62.1%, respectively, for NASH patients that underwent LT[42]. Overall graft survival was also reported similar between NASH recipients vs those with non-NASH LT indications. Mortality in patients transplanted for NASH was mainly attributed to cardio/cerebrovascular disease and infection rather than liver-related complications. However, the true impact of recurrent or de novo NAFLD on overall and graft survival has not been largely investigated. Dureja et al[43] studied 88 liver transplant recipients and found no difference in post-LT survival between patients with NAFLD recurrence and those without in a follow-up period of 5 years[43]. More relevant studies with longer follow-up time are necessary to clarify whether post-LT NAFLD per se is associated with increased mortality in the post-transplant setting.
There are scarce data regarding the treatment of NAFLD in liver transplant patients. Main treatment strategies include lifestyle modifications, pharmacotherapy, bariatric surgery, and alteration in immunosuppression therapy[44]. The first approach in the management of post-LT NAFLD is lifestyle modification including adequate physical activity, weight loss, and calorie restriction. No drugs have been approved for the treatment of NAFLD and none of the proposed pharmacotherapies has been studied in the post-transplant population. In the latest American Association for the Study of Liver Diseases and European Association for the Study of the Liver guidelines, pioglitazone, and vitamin E, either as monotherapy or as combination therapy, have been proposed as a potential treatment approach in biopsy-proven NASH patients[45]. However, there are concerns about the safety of long-term use of vitamin E, as it has been associated with an increased risk of prostate cancer and hemorrhagic stroke[46,47]. Pioglitazone has been associated with weight gain and should be, therefore, cautiously recommended in transplanted patients, for fear of exacerbating post-LT obesity and PTMS[48]. Bariatric surgery is recommended in cases where obese patients cannot achieve weight reduction following LT; however, there are concerns regarding the potential malabsorption and altered pharmacokinetics of immunosuppressive drugs[49,50]. Optimization of immunosuppression is of vital importance to reduce drug-induced metabolic risks and subsequent NAFLD in the post-LT period. Early steroid withdrawal, minimization, and alterations of immunosuppressive regimens based on patient’s metabolic complications are common approaches in the management of PTMS. More specifically, in cases where hypertension is the major metabolic complication, conversion from cyclosporine to tacrolimus has been shown to have a beneficial effect on blood pressure[51]. Similarly, reducing tacrolimus dosage or switching to another immunosuppression regimen has been associated with better glycemic control in recipients with new-onset T2DM[52]. mTOR inhibitors, on the other hand, should be avoided in cases of severe uncontrolled dyslipidemia[32,33].
Post-LT NAFLD remains a great challenge for hepatologists and transplant surgeons. Early detection of modifiable risk factors plays a crucial role in preventing disease occurrence. There is an unmet need for specific recommendations regarding both NAFLD screening and management in the post-transplant setting. Post-LT diagnosis tends to be underdiagnosed due to poor sensitivity of routine imaging modalities, whereas liver biopsy is not routinely used for NAFLD diagnosis, due to its invasive nature and possible complications. Regarding disease management, while numerous studies have investigated potential treatment approaches for NAFLD in non-transplant patients, there are scarce data on liver-transplant recipients, with most treatment strategies being extrapolated from recommendations in the general population. However, certain limitations in transplanted patients, such as reduced physical activity, immunosuppressive therapy, and drug-drug interactions with NAFLD treatment regimens, as well as treatment dilemmas regarding minimization or alteration of immunosuppression therapy in the setting of PTMS remain major problems for hepatologists. Prospective, longitudinal studies in liver transplant recipients are necessary to optimize screening, disease monitoring, and treatment in this special patient population.
Provenance and peer review: Invited article; Externally peer reviewed.
Peer-review model: Single blind
Specialty type: Transplantation
Country/Territory of origin: Greece
Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C
Grade D (Fair): D
Grade E (Poor): 0
P-Reviewer: Li Z, China; Wang F, China S-Editor: Fan JR L-Editor: Filipodia P-Editor: Fan JR
1. | Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23:8263-8276. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 418] [Cited by in F6Publishing: 450] [Article Influence: 64.3] [Reference Citation Analysis (6)] |
2. | Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005-2023. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2413] [Cited by in F6Publishing: 2542] [Article Influence: 211.8] [Reference Citation Analysis (1)] |
3. | Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2065] [Cited by in F6Publishing: 2221] [Article Influence: 170.8] [Reference Citation Analysis (0)] |
4. | Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5322] [Cited by in F6Publishing: 6903] [Article Influence: 862.9] [Reference Citation Analysis (0)] |
5. | Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038-1048. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1490] [Cited by in F6Publishing: 1922] [Article Influence: 240.3] [Reference Citation Analysis (1)] |
6. | Mikolasevic I, Filipec-Kanizaj T, Mijic M, Jakopcic I, Milic S, Hrstic I, Sobocan N, Stimac D, Burra P. Nonalcoholic fatty liver disease and liver transplantation - Where do we stand? World J Gastroenterol. 2018;24:1491-1506. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 69] [Article Influence: 11.5] [Reference Citation Analysis (0)] |
7. | Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547-555. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1211] [Cited by in F6Publishing: 1317] [Article Influence: 146.3] [Reference Citation Analysis (1)] |
8. | Sharma P, Arora A. Approach to prevention of non-alcoholic fatty liver disease after liver transplantation. Transl Gastroenterol Hepatol. 2020;5:51. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis (0)] |
9. | Pais R, Barritt AS 4th, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016;65:1245-1257. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 307] [Cited by in F6Publishing: 303] [Article Influence: 37.9] [Reference Citation Analysis (1)] |
10. | Shetty A, Giron F, Divatia MK, Ahmad MI, Kodali S, Victor D. Nonalcoholic Fatty Liver Disease after Liver Transplant. J Clin Transl Hepatol. 2021;9:428-435. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis (0)] |
11. | Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl. 2010;16:431-439. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 171] [Cited by in F6Publishing: 157] [Article Influence: 11.2] [Reference Citation Analysis (0)] |
12. | Matsuoka L, Chotai PN, Slaughter J, Campbell K, Kerr A, Hamel S, Garza C, Alexopoulos SP, Scanga A. A Single-Center Study of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Recurrence in Recipients of Liver Transplant for Treatment of Nonalcoholic Steatohepatitis Cirrhosis. Exp Clin Transplant. 2022;20:150-156. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis (0)] |
13. | Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, Fisher RA, Ham J, Sanyal AJ. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2001;7:363-373. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 297] [Cited by in F6Publishing: 307] [Article Influence: 13.3] [Reference Citation Analysis (0)] |
14. | Eshraghian A, Nikeghbalian S, Kazemi K, Shamsaeefar A, Geramizadeh B, Malek-Hosseini SA. Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis. HPB (Oxford). 2020;22:521-528. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
15. | Losurdo G, Castellaneta A, Rendina M, Carparelli S, Leandro G, Di Leo A. Systematic review with meta-analysis: de novo non-alcoholic fatty liver disease in liver-transplanted patients. Aliment Pharmacol Ther. 2018;47:704-714. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis (0)] |
16. | Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, Boillot O, Rubbia-Brandt L, Scoazec JY, Hadengue A. Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". Am J Gastroenterol. 2010;105:613-620. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 156] [Cited by in F6Publishing: 157] [Article Influence: 11.2] [Reference Citation Analysis (0)] |
17. | Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol. 2010;53:199-206. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 153] [Cited by in F6Publishing: 149] [Article Influence: 10.6] [Reference Citation Analysis (0)] |
18. | El Atrache MM, Abouljoud MS, Divine G, Yoshida A, Kim DY, Kazimi MM, Moonka D, Huang MA, Brown K. Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome. Clin Transplant. 2012;26:E505-E512. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 4.9] [Reference Citation Analysis (0)] |
19. | Tejedor-Tejada J, Valenzuela EF, Muñoz RN, Gómez LH, García-Pajares F, Álvarez CA, Sánchez-Martín F, Alonso-Martín C, Sánchez-Antolín G. De-novo nonalcoholic fatty liver disease at 5 years after liver transplantation: prevalence and predictive factors. Eur J Gastroenterol Hepatol. 2021;33:399-406. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
20. | Kappus M, Abdelmalek M. De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation. Clin Liver Dis. 2017;21:321-335. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis (0)] |
21. | Horiuchi K, Kogiso T, Sagawa T, Taniai M, Kotera Y, Egawa H, Tokushige K. Prevalence of fatty liver disease after liver transplantation and risk factors for recipients and donors. Ann Hepatol. 2022;27:100670. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
22. | Finkenstedt A, Auer C, Glodny B, Posch U, Steitzer H, Lanzer G, Pratschke J, Biebl M, Steurer M, Graziadei I, Vogel W, Zoller H. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis. Clin Gastroenterol Hepatol. 2013;11:1667-1672. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 6.0] [Reference Citation Analysis (0)] |
23. | Trunečka P, Míková I, Dlouhá D, Hubáček JA, Honsová E, Kolesár L, Lánská V, Fraňková S, Šperl J, Jirsa M, Poledne R. Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis. A post-transplant biopsy-based study. Dig Liver Dis. 2018;50:490-495. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis (0)] |
24. | Míková I, Neřoldová M, Hubáček JA, Dlouhá D, Jirsa M, Honsová E, Sticová E, Lánská V, Špičák J, Trunečka P. Donor PNPLA3 and TM6SF2 Variant Alleles Confer Additive Risks for Graft Steatosis After Liver Transplantation. Transplantation. 2020;104:526-534. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis (0)] |
25. | John BV, Aiken T, Garber A, Thomas D, Lopez R, Patil D, Konjeti VR, Fung JJ, McCollough AJ, Askar M. Recipient But Not Donor Adiponectin Polymorphisms Are Associated With Early Posttransplant Hepatic Steatosis in Patients Transplanted for Non-Nonalcoholic Fatty Liver Disease Indications. Exp Clin Transplant. 2018;16:439-445. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
26. | Watt KD. Metabolic syndrome: is immunosuppression to blame? Liver Transpl. 2011;17 Suppl 3:S38-S42. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 4.3] [Reference Citation Analysis (0)] |
27. | Chauhan K, Khan A, Chowdhury S, Ross HM, Parra NS, Halegoua-DeMarzio D. A Comprehensive Review on the Risk of Metabolic Syndrome and Cardiovascular Disease after Liver Transplantation. Livers. 2022;2:85-96. [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis (1)] |
28. | Pham PT, Pham PC, Lipshutz GS, Wilkinson AH. New onset diabetes mellitus after solid organ transplantation. Endocrinol Metab Clin North Am. 2007;36:873-90; vii. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 74] [Cited by in F6Publishing: 78] [Article Influence: 4.6] [Reference Citation Analysis (0)] |
29. | Canzanello VJ, Textor SC, Taler SJ, Schwartz LL, Porayko MK, Wiesner RH, Krom RA. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). Liver Transpl Surg. 1998;4:328-334. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 2.7] [Reference Citation Analysis (0)] |
30. | Hejlova I, Honsova E, Sticova E, Lanska V, Hucl T, Spicak J, Jirsa M, Trunecka P. Prevalence and risk factors of steatosis after liver transplantation and patient outcomes. Liver Transpl. 2016;22:644-655. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis (0)] |
31. | Galvin Z, Rajakumar R, Chen E, Adeyi O, Selzner M, Grant D, Sapisochin G, Greig P, Cattral M, McGilvray I, Ghanekar A, Selzner N, Lilly L, Patel K, Bhat M. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis. Liver Transpl. 2019;25:56-67. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 31] [Cited by in F6Publishing: 43] [Article Influence: 8.6] [Reference Citation Analysis (0)] |
32. | Morrisett JD, Abdel-Fattah G, Kahan BD. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc. 2003;35:143S-150S. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 3.1] [Reference Citation Analysis (0)] |
33. | Trotter JF, Wachs ME, Trouillot TE, Bak T, Kugelmas M, Kam I, Everson G. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl. 2001;7:401-408. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 3.1] [Reference Citation Analysis (0)] |
34. | de Graaf EL, Kench J, Dilworth P, Shackel NA, Strasser SI, Joseph D, Pleass H, Crawford M, McCaughan GW, Verran DJ. Grade of deceased donor liver macrovesicular steatosis impacts graft and recipient outcomes more than the Donor Risk Index. J Gastroenterol Hepatol. 2012;27:540-546. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 118] [Cited by in F6Publishing: 129] [Article Influence: 10.8] [Reference Citation Analysis (0)] |
35. | Saeed N, Glass L, Sharma P, Shannon C, Sonnenday CJ, Tincopa MA. Incidence and Risks for Nonalcoholic Fatty Liver Disease and Steatohepatitis Post-liver Transplant: Systematic Review and Meta-analysis. Transplantation. 2019;103:e345-e354. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 38] [Cited by in F6Publishing: 62] [Article Influence: 15.5] [Reference Citation Analysis (0)] |
36. | Kim H, Lee K, Lee KW, Yi NJ, Lee HW, Hong G, Choi Y, You T, Suh SW, Jang JJ, Suh KS. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation. Clin Transplant. 2014;28:521-529. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis (0)] |
37. | Miyaaki H, Miuma S, Taura N, Shibata H, Sasaki R, Soyama A, Hidaka M, Takatsuki M, Eguchi S, Nakao K. Risk Factors and Clinical Course for Liver Steatosis or Nonalcoholic Steatohepatitis After Living Donor Liver Transplantation. Transplantation. 2019;103:109-112. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis (0)] |
38. | Narayanan P, Mara K, Izzy M, Dierkhising R, Heimbach J, Allen AM, Watt KD. Recurrent or De Novo Allograft Steatosis and Long-term Outcomes After Liver Transplantation. Transplantation. 2019;103:e14-e21. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 49] [Cited by in F6Publishing: 67] [Article Influence: 13.4] [Reference Citation Analysis (0)] |
39. | Bhagat V, Mindikoglu AL, Nudo CG, Schiff ER, Tzakis A, Regev A. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl. 2009;15:1814-1820. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 136] [Cited by in F6Publishing: 127] [Article Influence: 8.5] [Reference Citation Analysis (0)] |
40. | Agopian VG, Kaldas FM, Hong JC, Whittaker M, Holt C, Rana A, Zarrinpar A, Petrowsky H, Farmer D, Yersiz H, Xia V, Hiatt JR, Busuttil RW. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg. 2012;256:624-633. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 183] [Cited by in F6Publishing: 190] [Article Influence: 15.8] [Reference Citation Analysis (0)] |
41. | Kennedy C, Redden D, Gray S, Eckhoff D, Massoud O, McGuire B, Alkurdi B, Bloomer J, DuBay DA. Equivalent survival following liver transplantation in patients with non-alcoholic steatohepatitis compared with patients with other liver diseases. HPB (Oxford). 2012;14:625-634. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis (0)] |
42. | Haldar D, Kern B, Hodson J, Armstrong MJ, Adam R, Berlakovich G, Fritz J, Feurstein B, Popp W, Karam V, Muiesan P, O'Grady J, Jamieson N, Wigmore SJ, Pirenne J, Malek-Hosseini SA, Hidalgo E, Tokat Y, Paul A, Pratschke J, Bartels M, Trunecka P, Settmacher U, Pinzani M, Duvoux C, Newsome PN, Schneeberger S; European Liver and Intestine Transplant Association (ELITA). Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study. J Hepatol. 2019;71:313-322. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 149] [Cited by in F6Publishing: 212] [Article Influence: 42.4] [Reference Citation Analysis (0)] |
43. | Dureja P, Mellinger J, Agni R, Chang F, Avey G, Lucey M, Said A. NAFLD recurrence in liver transplant recipients. Transplantation. 2011;91:684-689. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 117] [Cited by in F6Publishing: 124] [Article Influence: 9.5] [Reference Citation Analysis (0)] |
44. | Shaker M, Tabbaa A, Albeldawi M, Alkhouri N. Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities. World J Gastroenterol. 2014;20:5320-5330. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 84] [Article Influence: 8.4] [Reference Citation Analysis (0)] |
45. | Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol. 2018;24:3361-3373. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 354] [Cited by in F6Publishing: 339] [Article Influence: 56.5] [Reference Citation Analysis (5)] |
46. | Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306:1549-1556. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1218] [Cited by in F6Publishing: 1170] [Article Influence: 90.0] [Reference Citation Analysis (0)] |
47. | Schürks M, Glynn RJ, Rist PM, Tzourio C, Kurth T. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ. 2010;341:c5702. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 276] [Cited by in F6Publishing: 241] [Article Influence: 17.2] [Reference Citation Analysis (0)] |
48. | Aghamohammadzadeh N, Niafar M, Dalir Abdolahinia E, Najafipour F, Mohamadzadeh Gharebaghi S, Adabi K, Ahadi H. The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients. Ther Adv Endocrinol Metab. 2015;6:56-60. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis (0)] |
49. | Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, Raverdy V, Leteurtre E, Dharancy S, Louvet A, Romon M, Duhamel A, Pattou F, Mathurin P. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. Gastroenterology. 2015;149:379-88; quiz e15. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 510] [Cited by in F6Publishing: 517] [Article Influence: 57.4] [Reference Citation Analysis (3)] |
50. | Yemini R, Nesher E, Winkler J, Carmeli I, Azran C, Ben David M, Mor E, Keidar A. Bariatric surgery in solid organ transplant patients: Long-term follow-up results of outcome, safety, and effect on immunosuppression. Am J Transplant. 2018;18:2772-2780. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis (0)] |
51. | Neal DA, Gimson AE, Gibbs P, Alexander GJ. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight. Liver Transpl. 2001;7:533-539. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
52. | Tueche SG. Diabetes mellitus after liver transplant new etiologic clues and cornerstones for understanding. Transplant Proc. 2003;35:1466-1468. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 2.5] [Reference Citation Analysis (0)] |